Copenhagen, 2014-04-28 15:53 CEST (GLOBE NEWSWIRE) --
- Tuesday, 6 May 2014 from 08:00 – 11:00 ET
- Two keynote presentations from Key Opinion Leaders
- The event will be accessible also via a live video webcast with access to online slide presentations
Copenhagen, 25 April 2014 – Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL) informs that the company will host a Capital Markets Day for investors and analysts in New York on Tuesday, 6 May from 08:00 – 11:00 ET at the Four Seasons Hotel, 57 East 57 th Street, New York.
The event will feature two keynote presentations :
Nancy Thornberry , who has a 34 year industry career, most recently as Senior Vice President and Head of R&D for Merck’s global diabetes & endocrinology franchise, will speak on “The challenges and opportunities in the treatment of Type 2-Diabetes”.
Dr. Thomas Engstrøm , PhD, DMSc, Chief Physician, The Heart Center, Rigshospitalet, Copenhagen University Hospital, who will discuss Ischemic reperfusion injuries as a major challenge and unmet medical need in the treatment of Acute Myocardial Infarction (AMI).
Presentations will also be given by Zealand’s management, represented by Dr. David Solomon, President and CEO, and Dr. Torsten Hoffmann, Executive Vice President and CSO, who will give insight into the status and outlook for Zealand’s product portfolio with focus on value drivers in the short, mid- and long-term.
No material new information will be disclosed at the event.
Event details
| DATE: | Tuesday, 6 May 2014 |
| TIME: | 08:00 – 11:00 ET (webcast will start at 8:15am ET) |
| VENUE: | Four Seasons Hotel, 57 East 57 th Street – Metropolitan Suite, NYC |
| WEBCAST & REPLAY: | Can be accessed via http://wsw.com/webcast/cc/zeal.co/ or from Zealand’s website www.zealandpharma.com . Participants in the webcast are advised to register 10 minutes before the start. A replay will be available shortly after the event, also from Zealand’s website |
| REGISTRATION: | Rhonda Chiger, (RxCommunication) e-mail: rchiger@RxIR.com , Tel.: +1 917-322-2569 |
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications Tel: +45 5060 3689, email: hlh@zealandpharma.com
About Zealand Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia® under a license agreement with Sanofi. Lyxumia® is approved in several countries globally, including Europe and Japan. In the US, an NDA is planned to be submitted in 2015, after completion of a cardiovascular outcome study, ELIXA. In February 2014, Sanofi started the pivotal Phase 3 clinical program for the Lantus®/Lyxumia® combination product (LixiLan).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information : www.zealandpharma.com
Follow us on Twitter @ZealandPharma
